Oran Park Mask External Clinical Study (3) Marketing Claims Study

Obstructive Sleep Apnea Clinical Trial

Official title:

Assessment of the Seal, Comfort, Usability, and Performance of the Oran Park Mask System in the Home Environment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06079866
• Other study ID #: SLP-23-04-01
• Secondary ID: D646-159
• Status: Completed
• Phase: N/A
• Start date: October 4, 2023
• Est. completion date: November 20, 2023

Study information

• Verified date: October 2023
• Source: ResMed
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this prospective, randomized, open label, cross over study to assess the seal, comfort, usability, and performance of the prototype Oran Park mask system (referred to as Mask A in this study protocol) in the home environment. Comparisons will be made against Fisher & Paykel's Evora Full mask system (referred to as Mask B in this study protocol, an FDA cleared benchmark mask) and the participant's own mask. Patients diagnosed with Obstructive Sleep Apnea and are current CPAP users on a tube down full-face mask system will be recruited to the study to evaluate the Oran Park mask system and the Evora Full mask system for up to 7 nights each, in the home environment, whilst using their own CPAP device. The overall purpose is to evaluate the performance of the prototype Oran Park mask system compared to an FDA cleared benchmark mask (Evora Full) in relation to seal, comfort, usability, ease of use, preference, AHI, and objective therapy data.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: November 20, 2023
• Est. primary completion date: November 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants willing to give written informed consent
• Participants who can read and comprehend English
• Participants who = 18 years of age
• Participants being treated for OSA for = 12 months
• Participants who have met CMS compliance for CPAP therapy over the last 3 months
• Participants who have been using a ResMed cloud connected AirSense10 or AirSense 11 device compatible with AirView, for more than 12 months
• Participants currently using a suitable mask system*
• Participants who can trial the masks for up to 7 nights each
• Note*: Suitable mask system includes any tube down full face mask (e.g. AirFit F30, AirFit F20, AirTouch F20, AirFit F10, Quattro Air, Quattro Fx, Mirage Quattro, Simplus, Amara, Amara Gel, Comfort gel Full Face Mask, Evora Full)

Exclusion Criteria:

• Participants using Bi-level flow generators
• Participants who are or may be pregnant
• Participants with a pre-existing lung disease/ condition that would predispose them to pneumothorax (for example: COPD, lung cancer; fibrosis of the lungs; recent (< 2years) case of pneumonia or lung infection; lung injury.
• Participants who or whose bed partner has implantable metallic implants in the head, neck and chest region affected by magnetic fields (Non-ferrous implants may be acceptable)
• Participants who use a rental unit for AirSense 10 or AirSense 11 device
• Participants believed to be unsuitable for inclusion by the researcher

Related Conditions & MeSH terms

• Obstructive Sleep Apnea
• Sleep Apnea, Obstructive

Intervention

Device:
• Mask A (Oran Park Mask) then Mask B (Evora Mask)
Mask A (Oran Park Mask) for 7 days followed by Mask B (Evora Mask) for 7 days
• Mask B (Evora Mask) then Mask A (Oran Park Mask)
Mask B (Evora Mask) for 7 days followed by Mask A (Oran Park Mask) for 7 days.

Locations

Country	Name	City	State
United States	Clayton Sleep Institute	Saint Louis	Missouri
United States	Sleep Data	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
ResMed

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	11 point Likert Scale Questionnaire	• Subjective scores will be collected from subjects on each attribute being assessed (e.g. seal, comfort, ease of use etc.). Scores will be collected using an 11-point Likert Scale Questionnaire. Minimum value will be zero. Maximum value will be 10. A higher score indicates better outcomes. A score of 10 is considered very favorable, and a score of 0 is very unfavorable.	7 days
Secondary	Apnea Hypopnea Index (AHI)	• The AHI recorded by the subject's PAP device while using their own mask will be compared to the AHI recorded by the subject's PAP device while using the Oran Park mask and the Evora Mask. The AHI will be obtained from the ResMed AirView Compliance Reports downloaded from the subject's PAP device during the study visits.	7 days
Secondary	Leak	The median air leak (L/minute) recorded by the subject's PAP device while using their own mask will be compared to the median air leak (L/minute) recorded by the subject's PAP device while using the Oran Park mask and the Evora mask. The median air leak will be obtained from the ResMed AirView Compliance Reports downloaded during the study visits.	7 days
Secondary	Pressure Differences	The median air pressure (cmH2O) used during PAP therapy recorded by the subject's PAP device while using their own mask will be compared to the median air pressure (cmH2O) recorded by the subject's PAP device while using the Oran Park mask and the Evora mask. The median air pressure levels will be obtained from the ResMed AirView Compliance Reports downloaded from the subject's PAP device during the study visits.	7 days
Secondary	Compliance	The subject's average daily hours of use of PAP therapy recorded by the subject's PAP device while using their own mask will be compared to the average daily hours of use recorded by the subject's PAP device while using the Oran Park mask and the Evora mask. The average daily hours of use will be obtained from the ResMed AirView Compliance Reports downloaded from the subject's PAP device during the study visits.	7 days